Pharmacyclics Switzerland Gmbh

This study provides continued access to the cancer drug ibrutinib for patients who benefited from it in previous clinical trials but cannot obtain it through regular commercial channels. It allows about 300 patients with various blood cancers or solid tumors to keep receiving the…